加载中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$29.105
−US$0.255 · -0.87%
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
常规交易时段
US$29.105
−US$0.255 · -0.87%
盘中时间采用ET。市场数据可能有所延迟。
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
日内区间
当前US$29.105
52周区间
当前US$29.105
盘中时间采用ET。市场数据可能有所延迟。
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
日内区间
当前US$29.105
52周区间
当前US$29.105
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.72亿 USD | 2亿 USD | 1.3亿 USD | 8859.5万 USD | 7247.6万 USD |
| 销货成本 | 6793.4万 USD | 4924.5万 USD | 3964万 USD | 2538.3万 USD | 1821.4万 USD |
| 毛利 | 2.04亿 USD | 1.5亿 USD | 9055.3万 USD | 6321.2万 USD | 5426.2万 USD |
| 研究与开发 | 1284.6万 USD | 1223万 USD | 665.2万 USD | 305万 USD | 1108.4万 USD |
| 销售、一般及管理费用 | 1.53亿 USD | — | — | — | 3981.5万 USD |
| 营业费用 | 1.66亿 USD | 1.42亿 USD | 9012.2万 USD | 6129.3万 USD | 5264.8万 USD |
| 利息支出 | 2418万 USD | 2278.6万 USD | 2132.4万 USD | 724.4万 USD | 543.6万 USD |
| 折旧和摊销 | 1967.7万 USD | 1453.7万 USD | 1234万 USD | 366.5万 USD | 239.6万 USD |
| 营业利润 | 3860.9万 USD | 882.2万 USD | 43.1万 USD | 191.9万 USD | 161.4万 USD |
| 净利润 | −513.9万 USD | −1748.1万 USD | −2441.1万 USD | −1408.6万 USD | −1800.7万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$66.50
上涨空间 128.48%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2013年2月8日 | 1:5 | — | — |
股票拆分 | 2012年2月24日 | 1:8 | — | — |
股票拆分 | 2007年9月28日 | 231:500 | — | — |
已生效 2013年2月8日
1:5
已生效 2012年2月24日
1:8
已生效 2007年9月28日
231:500
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3696.33万0.00%2.3万亿 USD0.03%US$381.62-0.09%
iShares Russell 2000 ETFIWM2477.66万0.03%787.4亿 USD0.19%US$278.16-0.28%
Vanguard Extended Market ETFVXF1422.45万0.01%954亿 USD0.05%US$234.13-0.37%
iShares Russell 2000 Growth ETFIWO873.43万0.06%139.17亿 USD0.24%US$354.82-0.55%
Dimensional - US Small Cap ETFDFAS838.2万0.02%338.69亿 USD0.31%US$78.29-0.08%
State Street SPDR S&P Pharmaceuticals ETFXPH762.27万1.65%4.62亿 USD0.35%US$64.28-0.57%
Vanguard Russell 2000 ETFVTWO686.52万0.04%180亿 USD0.06%US$112.36-0.27%
Fidelity Enhanced Small Cap ETFFESM565.88万0.09%64.1亿 USD0.28%US$45.375-0.19%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASState Street SPDR S&P Pharmaceuticals ETFXPHVanguard Russell 2000 ETFVTWOFidelity Enhanced Small Cap ETFFESMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
